Eledon Pharmaceuticals Inc. (ELDN)
Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting
Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting
📈 **POSITIVE** • Medium confidence analysis (65%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (80%) **Content type:** Clinical